Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma - Wikidata - awgldk - TriplyDB

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

http://www.wikidata.org/entity/Q33382596

about

Antiangiogenic therapy for high-grade glioma Anti-angiogenic therapy for high grade glioma Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma Recent advances in the molecular understanding of glioblastoma Malignant gliomas: old and new systemic treatment approaches The evolving roles and controversies of radiotherapy in the treatment of glioblastoma The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve Recurrent Glioblastoma: Where we stand Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma Bevacizumab for glioblastoma Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization Nonsurgical treatment of recurrent glioblastoma Targeting Aggressive Cancer Stem Cells in Glioblastoma Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial Biomarkers for glioma immunotherapy: the next generation Twisted tango: brain tumor neurovascular interactions An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Molecular biology of gliomas: present and future challenges Targeted therapy in advanced bladder cancer: what have we learned?Will kinase inhibitors make it as glioblastoma drugs?Practical management of bevacizumab-related toxicities in glioblastoma An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Contemporary murine models in preclinical astrocytoma drug development Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Gliomas and the vascular fragility of the blood brain barrier Emerging targeted therapies for glioma.Survival in glioblastoma: a review on the impact of treatment modalities.Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.It is time to include patients with brain tumors in phase I trials in oncology

P2860

Q24193485-44BB4FEA-65A8-4AC0-AB9F-322BBB07E2B5 Q24240185-CDFEC9B1-F688-4365-BC48-57874C6675BF Q24295370-84DDB9C2-86BE-4B45-B408-04F7FA9D7609 Q24564890-ED81F334-E4FB-4AF7-A408-4080A31A028C Q24632791-5ABAF1B3-27C1-41A8-936E-9BA603FE635D Q24632928-743D4A4E-9D27-49A5-BFC0-E3FCDE92413B Q26744387-AB7EE85F-04D7-45C2-8BA9-9815FE4B17F6 Q26746622-FCC4B172-2D76-447C-A786-14ABC8843A75 Q26752321-67B7BD12-583E-4324-BE50-6F722266C13B Q26764947-74722CAF-E8AD-4EF9-8E88-688D1E51C40A Q26765042-081A083D-74FC-4FAC-9DA7-CF9010DE1DA1 Q26767169-DA183A01-C0F8-4722-98EB-82C69F508558 Q26776307-9A6F4EFB-79E3-4D4E-A3F6-81AE94B3C395 Q26781833-659404BB-D2E9-43AD-AF8E-59E51AE538D7 Q26795560-282976B9-C1B4-4701-8912-3FF80834A620 Q26799983-6AFBE174-DEA5-44A4-A160-54616830A499 Q26800355-FC5CB422-5915-4842-BD60-7FFF08246CB1 Q26822717-E76EB2A8-40C0-41A0-9A28-E5F119E7D848 Q26824557-D5051C20-C72A-47AC-B274-2F581C4C1318 Q26824777-1FCF4E82-9BCF-4A6C-8585-442196E16589 Q26825496-36C27185-8665-439E-96F5-138B22F687CE Q26849613-E37938E6-CFB2-4219-8F1C-C0158B3EDD64 Q26852232-42F7D086-B288-4703-92D4-56370532C40A Q26853308-00BDE113-0318-46E7-AC38-A400F0977520 Q26853516-7BDDDD97-B8EE-45E0-8A0B-A7F6C51EBB9B Q27001295-5CDCD4B4-2ED9-4B27-AFD9-CAF2A3C231DE Q27009469-A94B7766-EF12-4554-AB7B-B64974BD18B9 Q27012684-A64FC9B2-E37D-4E8F-A3A8-1F786105D12C Q27015852-0348E4BD-E7AA-4845-95D8-2090D27E8B60 Q27024830-CBDA6DBE-4C5E-4FAF-B53D-04CDCAA07680 Q27026937-52F90131-7102-461C-A7EE-2611EBBA2788 Q28073057-0399E39B-DBFE-4046-8D85-DB90383C84E7 Q28078539-AF48772B-1F0A-49E9-8C88-F4031F9997A5 Q28081953-EFF6623B-2AFD-43A5-AA7E-EBF7AE5FA365 Q30241853-1470079E-A07E-4792-84F7-3C994E8DE2AA Q30251810-A8F15C31-9F47-40C5-95F6-728A0497BFEB Q30278053-6EE4252B-5198-47D2-BF05-8490A33C7556 Q30300986-4B793786-98E5-4474-8E1D-4C6CF13ABE7E Q30301304-A2445AE4-EECC-4737-8D66-0820FD782308 Q30359570-3B899AFF-F846-4295-BB19-D3A5142E9590

P2860

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

http://www.wikidata.org/entity/Q33382596

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@ast

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@en

type

label

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@ast

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@en

prefLabel

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@ast

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@en

P1433

Q33382596-80DD1C59-0AAF-422B-AD38-C31670CACB8A

P1476

Q33382596-34FA777B-8612-49B1-88EF-7116CF2865C3

P2093

Q33382596-06C7CFAA-E7F1-4F88-8854-B167788967D4

Q33382596-11F10738-2C63-437C-9360-409ECFB952BD

Q33382596-31B811C1-28E6-4770-AE18-976AF1842716

Q33382596-34077038-7A45-4A46-AAFD-DA1813777527

Q33382596-36D26F24-87D7-4D15-898B-D9E7CDB02215

Q33382596-43E04B98-7F99-450F-A744-AD180A76F847

Q33382596-46507F36-502A-4F49-B590-F0EE614AC6B9

Q33382596-4CD2CF19-9153-428E-897B-A430F064147A

Q33382596-A7932E7E-BF84-4478-84E6-D390B84AA44D

Q33382596-AF786B9B-8FAB-4329-A14A-85F0507E13E3

P2860

Q33382596-07EC8EF3-A62F-4C86-8916-13354B8F6B90

Q33382596-1F9B10CE-45FA-4A9E-9638-E48E8DE63A5B

Q33382596-48336213-5783-469E-9E82-90AE8BDC3199

Q33382596-4F8A669C-DF69-4CFD-B501-4CCE1C504A28

Q33382596-50944D26-3DF4-409E-B95A-59A5E85B5EC5

Q33382596-62FD0C61-2AF9-4D8E-98F0-6A4D8D67F900

Q33382596-850D2ED3-0D48-43E9-AEBD-86CC284C22B1

Q33382596-92B664CD-C568-47D9-9E4D-B1F8463FC9FD

Q33382596-93DB0537-DE60-499C-9F8A-CC0DD99C9D2F

Q33382596-9807ED64-7261-4EC7-91B9-9B1EF96FD7F8

P304

Q33382596-08BA2853-BB10-4310-B7A8-2C2C3750B82E

P31

Q33382596-B293E661-83A5-45BB-9AF0-E2315E26A33E

P356

Q33382596-1BDE6C59-DED0-4983-8F6E-2FAD0EB8A1B5

P407

Q33382596-9416B09E-4904-4F13-8CAD-CCE3A748D7D7

P433

Q33382596-11A1B9DD-F4D7-471B-8074-E5E32033EF0C

P478

Q33382596-7B5DEA10-8CB2-41EF-B8C8-DD4951CF4BCA

P50

Q33382596-76F11791-C550-490B-A124-3AF39DF20F72

P577

Q33382596-114C8F2E-B793-47FD-A9ED-53A5C1A4408D

P698

Q33382596-682AFE6D-548B-4A58-8E93-C0F178F82084

P921

Q33382596-18AF8FF5-B855-4484-B7EF-40AE25453496

Q33382596-BFBACDE4-907D-4CC1-8C42-DC410E773315

P932

Q33382596-9BBD75BC-DB6C-4ED5-97C6-C931E65ADDF5

P356

JCO.2008.16.3055

P1433

Journal of Clinical Oncology

P1476

Phase II trial of single-agent ...... sion in recurrent glioblastoma

@en

P2093

Cheryl Royce

http://www.w3.org/2001/XMLSchema#string

Howard A Fine

http://www.w3.org/2001/XMLSchema#string

Irene Stroud

http://www.w3.org/2001/XMLSchema#string

John Park

http://www.w3.org/2001/XMLSchema#string

Kevin Camphausen

http://www.w3.org/2001/XMLSchema#string

Kraig Moore

http://www.w3.org/2001/XMLSchema#string

Lyndon Kim

http://www.w3.org/2001/XMLSchema#string

Megan Mackey

http://www.w3.org/2001/XMLSchema#string

Nancy Garren

http://www.w3.org/2001/XMLSchema#string

Paul Duic

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Factors influencing survival in high-grade gliomas.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis

Glioma in the elderly.

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Response criteria for phase II studies of supratentorial malignant glioma.

P304

740-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.16.3055

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19114704

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2645088

http://www.w3.org/2001/XMLSchema#string